Amylyx (AMLX) Pharmaceuticals announced the first participant has been dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia, or PBH. The trial will evaluate avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation, in approximately 75 participants. Amylyx expects completion of recruitment in 2025, with topline data anticipated in the first half of 2026.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Biotech Alert: Searches spiking for these stocks today
- Amylyx doses first participant in LUMINA trial
- Amylyx upgraded to Outperform from Neutral at Mizuho
- Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position
- Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market